Tvardi Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Tvardi Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $5.53M | Mar 12, 2019 |
| FY2018 | Sep 30, 2018 | $5.06M | Mar 12, 2019 |
| FY2018 | Jun 30, 2018 | $2.87M | Mar 12, 2019 |
| FY2017 | Dec 31, 2017 | $911.0K | Mar 15, 2018 |
| FY2018 | Mar 31, 2017 | $911.0K | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $86.0K | Mar 15, 2018 |
| FY2017 | Jun 30, 2016 | $79.0K | Mar 15, 2018 |
| FY2017 | Mar 31, 2016 | $7.0K | Mar 15, 2018 |
| FY2017 | Dec 31, 2015 | $3.80M | Mar 15, 2018 |
| FY2016 | Sep 30, 2015 | $2.44M | Mar 10, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $7.14M | Mar 11, 2025 |
| FY2024 | Dec 31, 2023 | $20.97M | Mar 11, 2025 |
| FY2024 | Dec 31, 2022 | $41.87M | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $23.03M | Mar 6, 2024 |
| FY2020 | Dec 31, 2020 | $112.09M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $9.27M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $5.63M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $8.09M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $4.51M | Feb 25, 2021 |
| FY2020 | Sep 30, 2019 | $5.79M | Feb 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.21M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($29.40M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($118.51M) | Mar 11, 2025 |
| FY2024 | Dec 31, 2022 | ($85.47M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | ($88.44M) | Mar 6, 2024 |
| FY2020 | Dec 31, 2020 | $78.91M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | ($16.51M) | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | ($25.07M) | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | ($28.92M) | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | ($28.61M) | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.75M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($28.11M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($121.50M) | Mar 11, 2025 |
| FY2024 | Dec 31, 2022 | ($87.54M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | ($89.08M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | $5.39M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | ($111.68M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($77.38M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($59.49M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($58.40M) | Mar 12, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.01M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $23.65M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $108.51M | Mar 11, 2025 |
| FY2024 | Dec 31, 2022 | $91.88M | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $82.70M | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | $107.85M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | $113.82M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $75.53M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $48.52M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $49.25M | Mar 12, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.50M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($18.31M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($92.08M) | Mar 11, 2025 |
| FY2024 | Dec 31, 2022 | ($78.73M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | ($60.09M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | ($5.49M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | ($109.23M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($22.30M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($54.83M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($47.38M) | Mar 12, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.05M | Mar 11, 2025 |
| FY2024 | Dec 31, 2023 | $2.38M | Mar 11, 2025 |
| FY2024 | Dec 31, 2022 | $43.0K | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $39.0K | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | $349.0K | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | $18.0K | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $73.0K | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $58.0K | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $717.0K | Mar 12, 2019 |
| FY2017 | Dec 31, 2015 | $20.0K | Mar 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.07M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $35.20M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $125.84M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $182.24M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $247.06M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $271.16M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $232.96M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $190.82M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $97.00M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $63.83M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.13M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $40.83M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $68.76M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $23.46M | Mar 6, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.95M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($91.13M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($62.06M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $158.78M | Mar 11, 2025 |
| FY2024 | Dec 31, 2021 | $227.52M | Mar 11, 2025 |
| FY2023 | Dec 31, 2020 | $249.00M | Mar 6, 2024 |
| FY2022 | Dec 31, 2019 | $186.71M | Mar 6, 2023 |
| FY2021 | Dec 31, 2018 | $133.63M | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $86.78M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $50.73M | Feb 27, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($110.45M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($92.24M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($684.75M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($566.23M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($480.76M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($392.32M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($400.73M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($294.35M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($220.34M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($162.17M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.73M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $31.61M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $51.78M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $63.74M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $13.45M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $31.68M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $18.31M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $15.08M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $9.39M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $12.09M | Mar 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (11) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (26) | Mar 11, 2025 |
| FY2024 | Dec 31, 2022 | (19) | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Mar 6, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2021 | Dec 31, 2019 | (2) | Mar 1, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (11) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (26) | Mar 11, 2025 |
| FY2024 | Dec 31, 2022 | (19) | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Mar 6, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2021 | Dec 31, 2019 | (2) | Mar 1, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.38M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 2.57M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 4.54M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | 53.80M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | 53.48M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | 49.87M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 46.72M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 39.55M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 32.66M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | 27.30M | Mar 15, 2018 |